Intranasal COVID-19 vaccines: From bench to bed
Summary: Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization. However, vaccination today failed to prevent the virus infection through the upper respiratory tract, which is partially due to the absence of mucosal immunity activation. Despite the emerging severe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-02-01
|
| Series: | EBioMedicine |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352396422000251 |
| _version_ | 1798026046378868736 |
|---|---|
| author | Aqu Alu Li Chen Hong Lei Yuquan Wei Xiaohe Tian Xiawei Wei |
| author_facet | Aqu Alu Li Chen Hong Lei Yuquan Wei Xiaohe Tian Xiawei Wei |
| author_sort | Aqu Alu |
| collection | DOAJ |
| description | Summary: Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization. However, vaccination today failed to prevent the virus infection through the upper respiratory tract, which is partially due to the absence of mucosal immunity activation. Despite the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, the next generation of COVID-19 vaccine is in demand and intranasal (IN) vaccination method has been demonstrated to be potent in inducing both mucosal and systemic immune responses. Presently, although not licensed, various IN vaccines against SARS-CoV-2 are under intensive investigation, with 12 candidates reaching clinical trials at different phases. In this review, we give a detailed description about current status of IN COVID-19 vaccines, including virus-vectored vaccines, recombinant subunit vaccines and live attenuated vaccines. The ongoing clinical trials for IN vaccines are highlighted. Additionally, the underlying mechanisms of mucosal immunity and potential mucosal adjuvants and nasal delivery devices are also summarized. |
| first_indexed | 2024-04-11T18:28:53Z |
| format | Article |
| id | doaj.art-958ddb8a14f040a59fa725990891b647 |
| institution | Directory Open Access Journal |
| issn | 2352-3964 |
| language | English |
| last_indexed | 2024-04-11T18:28:53Z |
| publishDate | 2022-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EBioMedicine |
| spelling | doaj.art-958ddb8a14f040a59fa725990891b6472022-12-22T04:09:32ZengElsevierEBioMedicine2352-39642022-02-0176103841Intranasal COVID-19 vaccines: From bench to bedAqu Alu0Li Chen1Hong Lei2Yuquan Wei3Xiaohe Tian4Xiawei Wei5Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, ChinaLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, ChinaCorresponding authors.; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, ChinaCorresponding authors.; Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610041, ChinaSummary: Currently licensed COVID-19 vaccines are all designed for intramuscular (IM) immunization. However, vaccination today failed to prevent the virus infection through the upper respiratory tract, which is partially due to the absence of mucosal immunity activation. Despite the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, the next generation of COVID-19 vaccine is in demand and intranasal (IN) vaccination method has been demonstrated to be potent in inducing both mucosal and systemic immune responses. Presently, although not licensed, various IN vaccines against SARS-CoV-2 are under intensive investigation, with 12 candidates reaching clinical trials at different phases. In this review, we give a detailed description about current status of IN COVID-19 vaccines, including virus-vectored vaccines, recombinant subunit vaccines and live attenuated vaccines. The ongoing clinical trials for IN vaccines are highlighted. Additionally, the underlying mechanisms of mucosal immunity and potential mucosal adjuvants and nasal delivery devices are also summarized.http://www.sciencedirect.com/science/article/pii/S2352396422000251COVID-19SARS-CoV-2Intranasal vaccineMucosalAdjuvant |
| spellingShingle | Aqu Alu Li Chen Hong Lei Yuquan Wei Xiaohe Tian Xiawei Wei Intranasal COVID-19 vaccines: From bench to bed EBioMedicine COVID-19 SARS-CoV-2 Intranasal vaccine Mucosal Adjuvant |
| title | Intranasal COVID-19 vaccines: From bench to bed |
| title_full | Intranasal COVID-19 vaccines: From bench to bed |
| title_fullStr | Intranasal COVID-19 vaccines: From bench to bed |
| title_full_unstemmed | Intranasal COVID-19 vaccines: From bench to bed |
| title_short | Intranasal COVID-19 vaccines: From bench to bed |
| title_sort | intranasal covid 19 vaccines from bench to bed |
| topic | COVID-19 SARS-CoV-2 Intranasal vaccine Mucosal Adjuvant |
| url | http://www.sciencedirect.com/science/article/pii/S2352396422000251 |
| work_keys_str_mv | AT aqualu intranasalcovid19vaccinesfrombenchtobed AT lichen intranasalcovid19vaccinesfrombenchtobed AT honglei intranasalcovid19vaccinesfrombenchtobed AT yuquanwei intranasalcovid19vaccinesfrombenchtobed AT xiaohetian intranasalcovid19vaccinesfrombenchtobed AT xiaweiwei intranasalcovid19vaccinesfrombenchtobed |